Skip to main content

Select Drug Profiles

FDA Approvals, Payers' Guide
Therapeutic Leap for Multiple Myeloma in 2015: Unprecedented FDA Drug Approvals
Caroline Helwick
Read More
FDA Approvals, Payers' Guide
Entresto (Sacubitril/Valsartan): First-in-Class Angiotensin Receptor Neprilysin Inhibitor FDA Approved for Heart Failure
Loretta Fala
Read More
FDA Approvals, Payers' Guide
Darzalex (Daratumumab): First Anti-CD38 Monoclonal Antibody Approved for Patients with Relapsed Multiple Myeloma
Lisa A. Raedler, PhD, RPh
Read More
FDA Approvals, Payers' Guide
Farydak (Panobinostat): First HDAC Inhibitor Approved for Patients with Relapsed Multiple Myeloma
Lisa A. Raedler, PhD, RPh
Read More
FDA Approvals, Payers' Guide
Fycompa (Perampanel Hydrate) Receives Expanded Indication for Primary Generalized Tonic-Clonic Seizures
Lisa A. Raedler, PhD, RPh
Read More
FDA Approvals, Payers' Guide
Imbruvica (Ibrutinib): First Drug Approved for the Treatment of Patients with Waldenström’s Macroglobulinemia
Lisa A. Raedler, PhD, RPh
Read More
FDA Approvals, Payers' Guide
Kyprolis (Carfilzomib) Received New Indications as Combination Therapy for Use in Relapsed and/or Refractory Multiple Myeloma
Lisa A. Raedler, PhD, RPh
Read More
FDA Approvals, Payers' Guide
Lonsurf (Trifluridine plus Tipiracil): A New Oral Treatment Approved for Patients with Metastatic Colorectal Cancer
Lisa A. Raedler, PhD, RPh
Read More
FDA Approvals, Payers' Guide
Ninlaro (Ixazomib): First Oral Proteasome Inhibitor Approved for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Lisa A. Raedler, PhD, RPh
Read More
FDA Approvals, Payers' Guide
Nucala (Mepolizumab): First IL-5 Antagonist Monoclonal Antibody FDA Approved for Maintenance Treatment of Patients with Severe Asthma
Loretta Fala
Read More
Page 115 of 244
Results 1141 - 1150 of 2434